Robert Karr

Robert W.
Karr is the founder of Euclises Pharmaceuticals, Inc. (2011).
Dr. Karr is also the founder of Indalo Therapeutics, Inc. Dr. Karr is currently the Executive Chairman & Chief Executive Officer at Cadre Bioscience LLC since 2019, President & Chief Executive Officer at Drosmed LLC, President & Director at Myonid Therapeutics Inc., and Managing Member at Startup Partners International LLC since 2010.
Former positions include Chief Executive Officer at Zevra Therapeutics, Inc., President, Chief Executive Officer & Director at Arch Oncology, Inc. (2015-2016), Independent Director at Idera Pharmaceuticals, Inc. (2005-2015), Independent Director at GTx, Inc. (2011), Non-Executive Director at Verseon Corp.
(2017-2018), Director at Tansna Therapeutics, Inc., Managing Director at Karr Pharma Consulting LLC, Director at Antegrin Therapeutics LLC, Senior Executive-Global Research & Development at Pfizer Inc. (2004), Vice President-Research & Development Strategy at Warner-Lambert Co., Principal at G.D.
Searle & Co., Inc. (1999), Faculty Member at the University of Iowa, Principal at Idera, Inc., Member at Startup Midwest Management LLC (2010), and Faculty Member at Washington University School of Medicine.
Education includes an undergraduate degree from Southwestern University (1971) and a doctorate from the University of Texas Medical Branch (1975).